72791-76-5

Basic information

• Product Name: N-CBZ-N,N-BIS(2-CHLOROETHYL)AMINE
• Synonyms: N-CBZ-N,N-BIS(2-CHLOROETHYL)AMINE;benzyl bis(2-chloroethyl)carbamate;bis(2-chloroethyl)carbamic acid benzyl ester;CarbaMic acid,N,N-bis(2-chloroethyl)-, phenylMethyl ester;Benzyl bis(2-chloroethyl)
• CAS NO: 72791-76-5
• Molecular Formula: C₁₂H₁₅Cl₂NO₂
• Molecular Weight: 276.16
• Product Categories: pharmacetical
• Mol File: 72791-76-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 376.9 °C at 760 mmHg
• Flash Point: 181.8 °C
• Appearance: /
• Density: 1.245 g/cm³
• Vapor Pressure: 6.99E-06mmHg at 25°C
• Refractive Index: 1.539
• Storage Temp.: 2-8°C
• PKA: -1.78±0.70(Predicted)
• CAS DataBase Reference: N-CBZ-N,N-BIS(2-CHLOROETHYL)AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-CBZ-N,N-BIS(2-CHLOROETHYL)AMINE(72791-76-5)
• EPA Substance Registry System: N-CBZ-N,N-BIS(2-CHLOROETHYL)AMINE(72791-76-5)

Safety Data

• Hazardous Substances Data: 72791-76-5(Hazardous Substances Data)

Usage

General Description

N-CBZ-N,N-BIS(2-CHLOROETHYL)AMINE, also known as Bendacarb, is an alkylating agent and a known anticancer drug. It is a nitrogen mustard derivative, similar to the chemotherapeutic drug Mechlorethamine. N-CBZ-N,N-BIS(2-CHLOROETHYL)AMINE has been shown to have cytotoxic effects on various cancer cell lines, particularly in the treatment of leukemia and lymphoma. It works by interfering with the DNA replication and cell division of cancer cells, ultimately leading to cell death. N-CBZ-N,N-BIS(2-CHLOROETHYL)AMINE is commonly used in combination with other chemotherapy drugs to improve its efficacy in treating a variety of cancers. However, it is important to note that N-CBZ-N,N-BIS(2-CHLOROETHYL)AMINE can have toxic side effects on normal cells as well, leading to potential complications for patients undergoing treatment.

InChI:InChI=1/C12H15Cl2NO2/c13-6-8-15(9-7-14)12(16)17-10-11-4-2-1-3-5-11/h1-5H,6-10H2

Upstream product

• 501-53-1 benzyl chloroformate 
• 334-22-5 N,N-bis(chloro-2-ethyl)amine 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Downstream Products

• 954409-68-8 1-benzyl 4-tert-butyl 4-(2-naphthyl)piperidine-1,4-dicarboxylate 
• 1101177-62-1 benzyl 8-azaspiro[4.5]deca-1,3-diene-8-carboxylate 
• 952151-38-1 5-benzyl-2-(tert-butyl) 1,2,5-oxadiazepane-2,5-dicarboxylate 
• 1138150-45-4 C₂₅H₃₁N₃O₆ 

Relevant articles and documents

Design and Scalable Synthesis of N-Alkylhydroxylamine Reagents for the Direct Iron-Catalyzed Installation of Medicinally Relevant Amines**

Secondary and tertiary alkylamines are privileged substance classes that are often found in pharmaceuticals and other biologically active small molecules. Herein, we report their direct synthesis from alkenes through an aminative difunctionalization reaction enabled by iron catalysis. A family of ten novel hydroxylamine-derived aminating reagents were designed for the installation of several medicinally relevant amine groups, such as methylamine, morpholine and piperazine, through the aminochlorination of alkenes. The method has excellent functional group tolerance and a broad scope of alkenes was converted to the corresponding products, including several drug-like molecules. Besides aminochlorination, the installation of other functionalities through aminoazidation, aminohydroxylation and even intramolecular carboamination reactions, was demonstrated, further highlighting the broad potential of these new reagents for the discovery of novel amination reactions.

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.